-
公开(公告)号:EP1666589A4
公开(公告)日:2006-10-04
申请号:EP04772194
申请日:2004-08-19
申请人: TAKARA BIO INC
发明人: IDENO MITSUKO , MURAKI NOBUKO , OGAWA KINUKO , KISHIMOTO MASAYUKI , ENOKI TATSUJI , SAGAWA HIROAKI , KATO IKUNOSHIN
CPC分类号: C12N5/0636 , C12N2501/58
摘要: It is intended to provide a process for producing cytotoxic lymphocytes characterized by involving the step wherein, by using a medium having a total concentration of serum and plasma in the medium of from 0% by volume and less than 5% by volume, at least one treatment selected from among the induction of cytotoxic lymphocytes, maintenance thereof and upscaled culture thereof is carried out in the presence of fibronectin, its fragment or a mixture of the same.
-
公开(公告)号:EP2028266A4
公开(公告)日:2010-08-11
申请号:EP07744884
申请日:2007-06-07
申请人: TAKARA BIO INC
发明人: MURAKI NOBUKO , IDENO MITSUKO , NAGAMINE KINUKO , TAKASHIMA FUYUKO , KOBAYASHI EIJI , KATO AKIKO , MARUI TAKAHIRO , SAGAWA HIROAKI , ENOKI TATSUJI , KATO IKUNOSHIN
IPC分类号: C12N5/00 , A61K35/12 , A61P37/02 , C07K14/78 , C07K19/00 , C12N5/0783 , C12N5/10 , C12N15/09
CPC分类号: C07K14/78 , A61K35/17 , A61K2039/5158 , C12N5/0636 , C12N2501/58 , C12N2533/52
摘要: A method for preparing lymphocytes characterized in that the method includes the step of culturing lymphocytes in the presence of a modified recombinant fibronectin fragment, in which a part of heparin binding domains of fibronectin overlaps. The method of the present invention gives a high cell proliferation rate, and the lymphocytes obtained by the present invention can be suitably used, for example, in adoptive immunotherapy, so that a significant contribution to the field of medicine is expected. In addition, according to the present invention, a novel modified recombinant fibronectin fragment is provided.
-
公开(公告)号:EP1916302A4
公开(公告)日:2009-10-21
申请号:EP06782667
申请日:2006-08-10
申请人: TAKARA BIO INC
发明人: MARUI TAKAHIRO , NAGAMINE KINUKO , MURAKI NOBUKO , KATO AKIKO , ENOKI TATSUJI , SAGAWA HIROAKI , KATO IKUNOSHIN
IPC分类号: C12N15/12 , A61K35/14 , A61P35/00 , C07K14/435 , C12N5/0783 , C12N5/10
CPC分类号: A61K35/17 , A61K35/26 , A61K2039/5154 , C07K14/78 , C12N5/0636 , C12N2501/51 , C12N2501/515 , C12N2501/58 , C12N2531/00 , C12N2533/52 , G01N33/547
-
公开(公告)号:EP1547608A4
公开(公告)日:2007-05-30
申请号:EP03784533
申请日:2003-08-06
申请人: TAKARA BIO INC
发明人: ENOKI TATSUJI , OGAWA KINUKO , ONOGI HIROMU , SUGIYAMA KATSUMI , MURAKI NOBUKO , SAGAWA HIROAKI , KATO IKUNOSHIN
CPC分类号: A61K36/232 , A23L2/52 , A23L33/105 , A23V2002/00 , A23V2200/328 , A23V2250/21
摘要: The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed for treating or preventing a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for enhancement of glucose uptake into a cell, and an agent for induction of an adipocyte differentiation, each comprising as an effective ingredient a processed product derived from a plant belonging to Umbelliferae.
摘要翻译: 对伴随有胰岛素水平或胰岛素应答障碍的疾病的预防剂或治疗剂,胰岛素样剂,食品,饮料或饲料,用于治疗或预防伴有胰岛素水平或胰岛素应答障碍的疾病,促进 将葡萄糖摄入细胞和诱导分化成脂肪细胞的药剂,每个药剂含有经处理的伞形科植物作为活性成分。
-
公开(公告)号:EP1563841A4
公开(公告)日:2009-08-12
申请号:EP03753964
申请日:2003-09-29
申请人: TAKARA BIO INC
IPC分类号: A23K1/16 , A23L1/30 , A61K31/353 , A61K36/23 , A61K36/232 , A61K36/282 , A61K36/896 , A61K36/8967 , A61P19/08 , A61P19/10 , A61P43/00 , C07D311/80 , A61K35/78 , G01N33/15 , G01N33/50
CPC分类号: C07D311/80 , A23K20/121 , A23L33/105 , A23V2002/00 , A61K31/353 , A61K36/23 , A61K36/232 , A61K36/282 , A61K36/8967 , A23V2200/306 , A23V2250/21
摘要: The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring promotion of osteogenesis or enhancement of bone morphogenetic protein production, an agent for promotion of osteogenesis or an agent for enhancement of bone morphogenetic protein production, and a food, beverage or feed for promotion of osteogenesis or enhancement of bone morphogenetic protein production, characterized in that each comprises as an effective ingredient a processed product derived from a plant. Also, the present invention relates to a method for measuring an enhancing action for bone morphogenetic protein production, a method for screening a substance having an enhancing action for bone morphogenetic protein production, and a method for preparing a substance having an enhancing action for bone morphogenetic protein production, each method using a specified cell.
-
公开(公告)号:EP1939278A4
公开(公告)日:2009-06-03
申请号:EP06810596
申请日:2006-09-27
申请人: TAKARA BIO INC
发明人: ENOKI TATSUJI , KATO AKIKO , MURAKI NOBUKO , IDENO MITSUKO , MARUI TAKAHIRO , SAGAWA HIROAKI , KATO IKUNOSHIN
IPC分类号: A61K35/14 , A61K35/76 , A61P1/16 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/16 , A61P35/00 , A61P37/04 , C07K14/78 , C12N5/0783 , C12N5/10 , C12N15/09
CPC分类号: C12N5/0636 , A61K35/17 , A61K38/19 , A61K39/00 , A61K39/0011 , A61K2039/5158 , C12N15/86 , C12N2501/515 , C12N2501/58 , C12N2740/10043 , A61K2300/00
摘要: Disclosed is a method for production of a T cell population capable of expressing CD45RA and also expressing at least one substance selected from the group consisting of CD62L, CCR7, CD27 and CD28. The method comprises the step of cultivating a cell population containing T cells in the presence of a fibronectin, a fragment thereof or a mixture of the fibronectin and the fragment.
-
公开(公告)号:EP1574506A4
公开(公告)日:2007-05-30
申请号:EP03753963
申请日:2003-09-29
申请人: TAKARA BIO INC
发明人: OHNOGI HIROMU , SUGIYAMA KATSUMI , MURAKI NOBUKO , ENOKI TATSUJI , SAGAWA HIROAKI , KATO IKUNOSHIN
IPC分类号: A23K1/16 , A23L1/30 , A61P25/00 , A61P43/00 , C07D311/58 , C07D311/80 , A61K31/353
CPC分类号: C07D311/80 , A23K20/121 , A23L33/10 , C07D311/58
摘要: A novel chalcone compound represented by the following general formula: wherein R1 and R2 form a hydroxydimethylhexane ring together with the carbon atoms respectively attached thereto, or R1 represents hydroxyl while R2 represents isohexenyl: its derivative or its salt; a remedy or a preventive for diseases with a need for the protection of nerve cells, the regulation of nitrogen monoxide (NO) production, the inhibition of aldose reductase or the regulation of interleukin production characterized by containing the above compound as the active ingredient; a nerve cell protecting agent, an NO production regulator, an aldose reductase inhibitor or an interleukin production regulator; and foods, drinks or feeds for treating or preventing the above diseases.
-
-
-
-
-
-